Objective: Treatment with inhaled nitric oxide improves oxygenation but not survival in mechanically ventilated patients with acute respiratory distress syndrome, but the effect may depend on the severity of hypoxemia. Our objective was to determine whether nitric oxide reduces hospital mortality in patients with severe acute respiratory distress syndrome (PaO 2 /FiO 2 ≤ 100 mm Hg) but not in patients with mild-moderate acute respiratory distress syndrome (100 < PaO 2 /FiO 2 ≤ 300 mm Hg) at the time of randomization. Data Sources: Data were collected from Medline, Embase, and Cochrane CENTRAL electronic databases (inception to May 2013); proceedings from five conferences (to May 2013); and trial registries (http://www.clinicaltrials.gov and http://www.controlled-trials.com). No language restrictions were applied. Study Selection: Two authors independently selected parallelgroup randomized controlled trials comparing nitric oxide with control (placebo or no gas) in mechanically ventilated adults or postneonatal children with acute respiratory distress syndrome. Data Extraction: Two authors independently extracted data from included trials. Trial investigators provided subgroup data. Metaanalyses used within-trial subgroups and random-effects models. Data Synthesis: Nine trials (n = 1,142 patients) met inclusion criteria. Overall methodological quality was good. Nitric oxide did not reduce mortality in patients with severe acute respiratory distress syndrome (risk ratio, 1.01 [95% Ci, 0.78-1.32]; p = 0.93; n = 329, six trials) or mild-moderate acute respiratory distress syndrome (risk ratio, 1.12 [95% Ci, 0.89-1.42]; p = 0.33;
Inhaled Nitric Oxide Does Not Reduce Mortality in Patients With Acute Respiratory Distress Syndrome Regardless of Severity: Systematic Review and Meta-Analysis* n = 740, seven trials). Risk ratios were similar between subgroups (interaction p = 0.53). There was no between-trial heterogeneity in any analysis (I 2 = 0%). Varying the PaO 2 /FiO 2 threshold between 70 and 200 mm Hg, in increments of 10 mm Hg, did not identify any threshold at which the nitric oxide-treated patients had lower mortality relative to controls. Conclusions: Nitric oxide does not reduce mortality in adults or children with acute respiratory distress syndrome, regardless of the degree of hypoxemia. Given the lack of related ongoing or recently completed randomized trials, new data addressing the effectiveness of nitric oxide in patients with acute respiratory distress syndrome and severe hypoxemia will not be available for the foreseeable future. (Crit Care Med 2014; 42:404-412) Key Words: acute respiratory distress syndrome; meta-analysis; nitric oxide; systematic review T he acute respiratory distress syndrome (ARDS) is characterized by the acute onset of hypoxemia and bilateral radiographic opacities not explained by cardiac failure or volume overload and arises in response to various direct and indirect pulmonary insults (1, 2) . These clinical features stem from inflammation and increased permeability of the alveolar-capillary membrane (3) that leads to alveolar filling and collapse. Hypoxemia results from ventilation-perfusion mismatching; pulmonary hypertension is an important associated finding. Use of inhaled nitric oxide (NO)-a selective pulmonary vasodilator with anti-inflammatory properties (4, 5)-was anticipated to improve oxygenation and clinical outcomes. However, meta-analyses of randomized controlled trials (RCTs) in adults and postneonatal children have shown that NO, despite improving PaO 2 /FiO 2 by approximately 5-13% for the first 4 days of treatment (6), does not reduce mortality and increases the risk of renal failure (6) (7) (8) . Long-term follow-up of one RCT found no beneficial effect of NO on other outcomes, including hospital costs, workload in the iCU, discharge location, hospital readmissions, functional status, or quality of life (9) .
Despite the lack of evidence for NO and the high daily cost of USD 1,500-3,000 (10) (11) (12) , it continues to be used for approximately 7% of all patients with ARDS (13) and for 10% of other mechanically ventilated patients with refractory hypoxemia (14) . During the recent H1N1 influenza pandemic, NO was administered to a substantial minority of mechanically ventilated patients in academic and community hospitals: 8% in South Korea (15) , 12% in Europe (16) , and 14% in Canada (17) . Ongoing use of NO for severely hypoxemic patients may be explained by their underrepresentation in RCTs. Such patients would be expected to be at high short-term risk of death due to hypoxemia and therefore likely to benefit from NO-mediated improvement in oxygenation.
The objective of this systematic review, performed in collaboration with investigators who led the seminal trials of NO, was to determine whether NO reduces mortality in patients with severe ARDS. The primary a priori hypothesis was that NO would reduce mortality in patients with severe ARDS (PaO 2 /FiO 2 ≤ 100 mm Hg) but not in patients with mildmoderate ARDS (100 < PaO 2 /FiO 2 ≤ 300 mm Hg) at the time of randomization. We also planned a priori to conduct similar comparisons of the more versus less hypoxemic subgroups using PaO 2 /FiO 2 thresholds ranging from 70 to 200 mm Hg, in increments of 10 mm Hg, to determine whether there is a threshold for which NO reduces mortality in the more hypoxemic subgroup.
MATERIALS AND METHODS

Search Strategy
We (N.K.J.A., J.O.F.) updated our previous search (6) 
Study Selection
Two reviewers (N.K.J.A., J.O.F.) independently screened studies for inclusion, retrieved potentially relevant studies, and decided on study eligibility. We selected parallel-group RCTs enrolling adults or children (excluding neonates), with more than or equal to 80% of patients, or a separately reported subgroup, having ARDS (using authors' definitions). included trials compared NO with control (placebo or no gas) for treatment (not prevention) of ARDS, reported all-cause mortality at any time, and had less than 50% of patients crossing over from control to NO arms. We included trials with cointerventions (such as prone ventilation or recruitment maneuvers)
www.ccmjournal.org applied equally in NO and control groups. We did not consider cause-specific mortality (e.g., refractory hypoxemia vs multiple organ failure).
Data Abstraction and Validity Assessment
From included trials, two reviewers had previously independently abstracted trial data and methodology, including method of randomization and allocation concealment; blinding of caregivers and outcomes assessors; number of postrandomization withdrawals; and standardization or similar application of mechanical ventilation, weaning, and sedation in treatment groups (6) . Disagreements were resolved by consensus. For the current review, authors of included trials provided previously unpublished trial data for subgroups of patients defined by PaO 2 /FiO 2 ratio. Two reviewers (N.K.J.A., J.O.F.) verified outcomes data against previously published data from the same trials, where possible.
Quantitative Data Synthesis
The primary outcome was mortality in the subgroup of patients with severe ARDS (PaO 2 /FiO 2 ≤ 100 mm Hg) compared with that in patients with mild-moderate ARDS (100 < PaO 2 /FiO 2 ≤ 300 mm Hg) at the time of randomization. We selected these categories based on the recent Berlin consensus conference (2) that categorized ARDS severity based on degree of hypoxemia as mild (200 < PaO 2 /FiO 2 ≤ 300 mm Hg), moderate (100 < PaO 2 /FiO 2 ≤ 200 mm Hg), and severe (PaO 2 /FiO 2 ≤ 100 mm Hg). We also conducted similar analyses of mortality in more versus less hypoxemic subgroups using PaO 2 /FiO 2 thresholds ranging from 70 to 200 mm Hg in increments of 10 mm Hg. For one trial, the numbers of deaths and randomized patients were only available in groups defined by less than PaO 2 /FiO 2 threshold and more than or equal to PaO 2 / FiO 2 threshold, rather than less than or equal to threshold and more than threshold (19) .
Mortality was taken at hospital discharge, or if not available, at discharge from the iCU or at 28 or 30 days after randomization. Our analyses adhered to the intention-to-treat principle. in studies with two or more NO groups receiving different doses, we combined data from all doses to determine an overall effect for the NO group.
Two investigators (N.K.J.A., J.O.F.) performed all calculations independently. We used standard equations for random-effects models (20) in Excel 2007 (Microsoft, Redmond, WA) and verified analyses with outcome events in at least one treatment arm of each study with Review Manager 5.1 (The Cochrane Collaboration, Oxford, UK). We also verified analyses for the primary outcome using R version 2.15.2 (R Foundation for Statistical Computing, Vienna, Austria). We reported binary outcomes as risk ratios (RRs) with 95% Ci and considered p value of less than or equal to 0.05 (two-sided) as statistically significant.
For the primary outcome, we performed a z test of interaction between the RR for mortality in the subgroup of patients with PaO 2 /FiO 2 less than or equal to 100 mm Hg and the RR in the subgroup of patients with PaO 2 /FiO 2 more than 100 mm Hg, which tests the null hypothesis that the treatment effects in each subgroup are the same. We also conducted similar comparisons of the more versus less hypoxemic subgroups using other PaO 2 /FiO 2 thresholds as defined above. At each PaO 2 /FiO 2 threshold in the primary analyses, we included all trials with a calculable RR in either the hypoxemic or less hypoxemic subgroup. At each PaO 2 /FiO 2 threshold in secondary analyses, we only included trials with calculable RRs in both subgroups. Trials without a calculable RR in a particular subgroup (e.g., in the subgroup of patients with PaO 2 /FiO 2 ≤ 80 mm Hg) were those that randomized no patients to either NO or control in that subgroup. Trials that randomized patients to both NO and control in a particular subgroup and had zero deaths in both treatment arms were included by adding 0.5 to each cell, as described previously (21) .
We assessed between-study heterogeneity for each outcome using the I 2 measure (22, 23) , with suggested thresholds for low (25-49%), moderate (50-74%), and high (≥ 75%) values of I 2 . To assess for publication bias, we examined a funnel plot of treatment effect versus study precision.
RESULTS
Literature Search, Study Characteristics, and Methodologic Quality
We identified 2,221 citations from searches of electronic bibliographic databases and six citations from conference proceedings. We retrieved 35 records for detailed evaluation, of which 21 citations were excluded for the following reasons (Fig 1) : no mortality data (confirmed after author contact) (24) , review (25) , not randomized (26) (27) (28) (29) , not for treatment of ARDS (NO used postcardiac surgery (30) or lung transplantation (31) (32) (33) (34) (35) (36) , with left ventricular assist device (37), or for acute sickle cell pain crisis) (38) , crossover trial (39) , not ARDS and crossover trial (40) , duplicate (41) or partial duplicate (confirmed after author contact) (42) , or longer term follow-up of included trials (9, 43) . Four additional trials that otherwise met selection criteria were excluded because more than or equal to 50% patients crossed over from control to NO (44) (45) (46) (47) ; data from one of these trials were distributed in two articles (46, 48) . We found no trials actively recruiting patients or recently terminated in trial registries.
Nine trials enrolling 1,142 patients (19, (49) (50) (51) (52) (53) (54) (55) (56) met criteria for inclusion in our review ( Fig. 1; Table 1 ). Data from one study were presented in two abstracts (19, 57) . No new trials have been published since our previous review (6) , which provides a detailed description of the study characteristics. Four trials used a fixed NO dose of 5 (55, 56) or 10 ppm (19, 54) , one trial randomized patients to different doses (1.25-80 ppm) (49) , and the remaining trials used the lowest dose to achieve an oxygenation response (mean dose, 5.3 [51] , 9 [52] , 13 [50] , or 5-10 ppm [53] ). Trials continued NO until criteria for improvement (generally in oxygenation or requirement for positive end-expiratory pressure) were met. Overall methodological quality of included trials was good (Supplemental Table 1 , Supplemental Digital Content 1, http://links.lww.com/ CCM/A734) (6).
We obtained patient-level data on PaO 2 /FiO 2 ratio and mortality for seven trials. For one trial, we obtained overall and subgroup data on the 177 patients reported in the original publication (49) as well as 56 randomized patients that had treatment gas (NO or placebo nitrogen) prematurely discontinued before meeting oxygenation threshold criteria. The authors of one trial were unable to locate the original data files (51), and we were unable to establish contact with the corresponding author of another trial (50) .
Quantitative Data Synthesis
Considering all patients (19, (49) (50) (51) (52) (53) (54) (55) (56) , regardless of severity of hypoxemia, NO had no effect on mortality (RR, (Fig. 2) . The test for interaction was not statistically significant (p = 0.53), indicating that treatment effects were similar in subgroups with severe and mild-moderate ARDS. if the trial with a calculable RR in the PaO 2 /FiO 2 more than 100 mm Hg subgroup but not in the PaO 2 /FiO 2 less than or equal to 100 mm Hg subgroup (55) Substituting PaO 2 /FiO 2 thresholds from 70 to 200 mm Hg, in increments of 10 mm Hg, did not identify any cutpoint at which mortality improved in NO-treated patients relative to controls, in either the more or less hypoxemic subgroups (Fig. 3) . Secondary analyses that excluded data from all trials without a calculable RR in both subgroups at each threshold resulted in negligible changes. There was no evidence of statistical heterogeneity in any analyses (I = 0%). Visual inspection of the funnel plot did not suggest publication bias.
DISCUSSION
Main Findings
The main finding of this systematic review and meta-analysis is that NO does not reduce hospital mortality in patients with ARDS, regardless of the severity of hypoxemia. The effect of NO did not differ between more hypoxemic and less hypoxemic patients, regardless of the threshold of PaO 2 /FiO 2 ratio used to demarcate these subgroups. Given that no relevant ongoing or recently completed RCTs are currently registered, new data addressing the effectiveness of NO in patients with ARDS and severe hypoxemia will not be available for the foreseeable future.
Comparison With Other Studies
Other recent meta-analyses of NO found no improvement in mortality and an increased risk of renal failure despite modest improvements in oxygenation (7, 8) . Compared with these reviews, we excluded one trial (42) confirmed to have most patients co-enrolled in a larger included trial (52), another trial (24) confirmed after author contact not to have mortality data, and trials in which more than or equal to 50% of patients crossed over from control to NO (44) (45) (46) (47) . For one trial (55) also included in previous reviews (7, 8) , we included the two randomized groups that both received a recruitment manoeuvre but differed in the use of NO, and we excluded the third group that received NO alone. We used 30-day mortality instead of 90-day mortality for one trial (52) . Finally, we verified data in collaboration with primary trial investigators, and our metaanalysis is the first to use within-trial subgroup analysis to examine the effect of NO by baseline severity of hypoxemia. Our analytic approach was similar to a previous metaanalysis (58) of ventilation in the prone position, which may also be considered for severely hypoxemic patients with ARDS. in that study, pooled mortality data from subgroups of patients with acute hypoxemic respiratory failure showed that prone ventilation reduced mortality in patients with severe hypoxemia (PaO 2 /FiO 2 < 100 mm Hg) but not mild-moderate hypoxemia (PaO 2 /FiO 2 ≥ 100 mm Hg); this subgroup effect was statistically significant (58) .
There are several possible reasons why improvements in oxygenation are not linked to improved mortality in the case of NO. The prolonged fixed-dosing regimen used in most trials may have attenuated benefit over time because of increased sensitization (54) , dampening the oxygenation benefit while continuing to expose patients to possible toxic effects such as oxidative damage (59) . Even among the most severely hypoxemic patients, who may be expected to die of primary respiratory failure rather than multiple nonlung organ failure (60) , the small improvements in oxygenation due to inhaled NO may have been overwhelmed by injurious effects from a mechanical ventilation strategy used in most trials that did not strictly limit tidal volume or airway pressure. it is possible that the subgroup of patients with ARDS and cor pulmonale, (56) . In another trial, the numbers of deaths and randomized patients were available as less than Pao 2 /FIo 2 threshold and more than or equal to threshold, and mortality status was unavailable for two No and five control patients (19) . Finally, the number of deaths in the control group in one trial (53) differs from our previous meta-analysis (6) , in which one very late death (68 d) was not counted. Weight is the contribution of each study to the overall RR. For the Pao 2 /FIo 2 more than 100 mm Hg subgroup, weights do not add to 100% due to rounding. I 2 = percentage of total variation across studies from between-study heterogeneity rather than chance, Each black square and horizontal line denotes the point estimate and 95% CI for each trial's RR. The diamond signifies the pooled RR for all trials and for each subgroup. The diamond's center denotes the point estimate and the width denotes the 95% CI.
www.ccmjournal.org for whom clinicians may prioritize treatment with NO (61), would benefit from additional study in randomized trials.
Although NO does not improve mortality, follow-up of one trial (56) included in this review suggested that 6-month survivors who received NO had small improvements on some pulmonary function tests compared with those who received placebo (43) . However, the internal validity of the study was limited by loss to follow-up of approximately 70% of survivors and by the lack of information on smoking status. in addition, the functional implications of these data are unclear, given that 6-minute walk distance was not measured and other data showing that pulmonary function in ARDS survivors returns to normal at 1 year (62).
Strengths and Limitations
An important strength of our study is the inclusion of 93.7% of eligible patients in the subgroup analysis after confirmation of data from primary trial authors. The primary hypothesis that NO would reduce mortality in patients with severe hypoxemia was prespecified, biologically plausible, and analyzed using appropriate tests for subgroup effects (63) . The trials included in this meta-analysis exhibited some methodological diversity (different inclusion criteria and different NO dosing and duration). However, for our primary comparison, we used patient-level subgroups within trials, which produce similar distributions of trial-specific characteristics in the more and less hypoxemic subgroups.
Our review has limitations. First, we conducted a subgroup analysis based on baseline PaO 2 /FiO 2 ratio, which is commonly reported and is used to define the severity of ARDS (2). However, PaO 2 /FiO 2 is influenced by ventilator settings and hemodynamic management that were not standardized across trials. Unfortunately, most trials did not measure oxygenation index, an alternative measure of hypoxemia that incorporates mean airway pressure as a marker of the intensity of mechanical ventilation. Second, the number of patients in the severe ARDS subgroup was relatively small, limiting the statistical power of our analysis to detect true differences in mortality between subgroups. Third, clinicians may argue that the dose used in included studies was insufficient to improve gas exchange in the most severely hypoxemic patients, who would be expected to be at highest risk from imminent death due to hypoxemia. However, the trials included in this review suggest otherwise. Of the trials that titrated NO to achieve improved oxygenation (50) (51) (52) (53) , the lowest and most effective dose was 5-10 ppm in three trials (51) (52) (53) and ~13 ppm in the fourth trial (50) . These findings are consistent with a detailed dose-response study that found that the average increase in PaO 2 was maximal at 5 ppm (64) . Another trial in our review found that as the duration of NO treatment increased, a lower dose (1 ppm) than initially prescribed (10 ppm) was associated with the best improvement in oxygenation (54) . in the one trial that randomized patients to doses ranging from 1.25 to 80 ppm, the proportion of patients with an immediate oxygenation response was approximately 60%, with no significant differences among dose arms (49) . This trial also found day 28 survival without mechanical ventilation to be highest in the 5 ppm group, which was therefore chosen as the dose in a subsequent large trial (56) . (56) . In another trial, the numbers of deaths and randomized patients were available as less than Pao 2 /FIo 2 threshold and more than or equal to threshold, and mortality status was unavailable for two No and five control patients (19) . Weight is the contribution of each study to the overall RR. n (k) = number of randomized patients (trials) included for each subgroup at the Pao 2 /FIo 2 threshold. At Pao 2 /FIo 2 threshold values of 120 and 130 mm Hg, there are six trials in each subgroup, of which five trials are the same in both subgroups and one is different. As discussed in the text, secondary analyses at each threshold that excluded data from trials without a calculable RR in both subgroups resulted in negligible changes.
Finally, compared with a meta-analysis based on withintrial subgroups, individual patient data meta-analysis is more robust, since it can adjust for patient-level confounders and can explore effects of NO dose and duration. However, such an analysis is more statistically complex and would face challenges of ensuring complete availability and comparability of data among trials (65, 66) . in the case of NO, recent observational data (13) (14) (15) (16) (17) suggest that clinicians reserve NO primarily for severe hypoxemia, suggesting that this is the most clinically relevant factor to consider in subgroup analysis. Furthermore, given our findings, it seems unlikely that a more complex analysis would identify subgroups in which NO reduced mortality.
CONCLUSIONS
in conclusion, our systematic review and meta-analysis extend previous work by finding no beneficial effect of NO on mortality among patients with ARDS, regardless of the severity of hypoxemia at randomization. This subgroup analysis was prespecified, included data verified by primary trial investigators, and included almost all randomized patients eligible for analysis. Although wide Cis preclude the conclusion that NO has absolutely no clinical benefit among severely hypoxemic patients with ARDS, other evidence argues against its use even in this limited population. Such evidence includes an increased risk of renal dysfunction (6), the high cost of NO (10) (11) (12) , and the existence of alternative approaches (prone ventilation [58] and extracorporeal support [67] ) that have stronger evidence for clinical benefit. Given the evidence to date, it is highly unlikely that additional randomized trials of NO in severely hypoxemic patients, using different dosing strategies or duration, will be performed. Therefore, as currently dosed and administered, the routine use of NO in patients with ARDS, regardless of severity, should therefore be abandoned. in rare circumstances in which patients appear to be at great risk of imminent death from hypoxemia despite all other available treatments, NO could be considered.
